>
>
>
Quraxia specializes in the research and development of Antibody-Drug Conjugates (ADCs), monoclonal antibodies, and molecular profiling technologies to address difficult cancers like lung, throat, and pancreatic cancer. Our scientists combine deep expertise with modern platforms to deliver safer, more effective therapies.
What are ADCs?
ADCs are smart cancer drugs built from three key parts:
Antibody – targets and attaches to cancer-specific proteins.
Cytotoxic Drug – a powerful cell-killing compound.
Linker – a connector that ensures the drug is released only inside cancer cells.
This smart delivery minimizes harm to healthy tissues while making treatment more effective.
Our ADC Services
Custom linker molecule design & synthesis
Antibody-drug conjugation and characterization
Safety & efficacy testing (in vitro and in vivo)
Preclinical evaluation under regulatory standards
Scale-up for clinical manufacturing
We support all stages — from feasibility studies and lead optimization to preclinical trials and manufacturing development.
Monoclonal Antibody Development
We develop high-specificity monoclonal antibodies for use as:
Diagnostics: early cancer detection markers
Therapeutics: precision ADC targeting agents
Genomic & Proteomic Profiling
Using MALDI-MS and other advanced tools, we study:
DNA methylation
miRNA signatures
Protein and antibody markers
Critical oncogenes like EGFR, ALK, HER2, BRCA
This enables early diagnosis, better targeting, and improved patient response predictions.
